An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in[…]
Latest Immunotherapy Treatments
ONCOS-102 Improves Pleural Mesothelioma Survival
There is promising new data from the makers of ONCOS-102 that shows that the treatment can help improve the long-term survival of mesothelioma patients. ONCOS-102 was recently given Fast-Track approval by the FDA to speed up its development. ONCOS-102 is a modified adenovirus that infects cancer cells. The new mesothelioma[…]
The ONCOS-102 Vaccine Was Just Given the Fast-Track Designation
The ONCOS-102 immunotherapy vaccine was given the Fast-Track Designation, which will speed up regulatory approval. The vaccine is used to treat mesothelioma and other cancers. Targovax, which developed the treatment, is taking this as an endorsement from the FDA. Targovax is a small biotech company that mainly works with oncolytic[…]
Cholesterol Drugs Called Statins Could Help Extend Mesothelioma Sufferers’ Lives
A group of drugs called statins used for controlling cholesterol are showing that they can help mesothelioma patients taking PD-1 inhibitors survive longer. Researchers in Italy and the Netherlands found this information in an international study of 250 patients. The patients studied either had pleural mesothelioma or non-small cell lung[…]
The ONCOS-102 Vaccine is Still Showing Promising Results
The ONCOS-102 immunotherapy vaccine is still showing promising results. Information from November shows when patients take the treatment with chemotherapy, it helped patients survive a minimum of 18.2 months. The median overall survival was four months better in the experimental group compared to the control group. Targovax, the maker of[…]
A New T-Cell Treatment is Being Tested on Mesothelioma Patients
A new clinical trial at the Memorial Sloan Kettering Cancer Center is recruiting patients for a pleural mesothelioma study. The treatment involves T-cell therapy and is a very promising treatment for mesothelioma sufferers. The reason the study is being done is ATA2271, which is known as CAR T-cell therapy, was[…]
Opdivo and Yervoy Have Been Fully Approved for Treating Mesothelioma
A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent[…]
New Immuno-Radiology Treatment Being Tested on Mesothelioma
Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment[…]
Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]
Keytruda and Tumor Treating Fields Combination Could Soon be Used for Mesothelioma
A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding[…]
